title: Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates β-catenin expression.
abstract: Hydrogen sulfide-releasing aspirin (HS-ASA) is a novel compound with potential against cancer. It inhibited the growth of Jurkat T-leukemia cells with an IC₅₀ of 1.9 ± 0.2 μM whereas that of ASA was >5000 μM. It dose-dependently inhibited proliferation and induced apoptosis in these cells, causing a G₀/G₁ cell cycle arrest. HS-ASA down-regulated β-catenin protein levels and reduced mRNA and protein expression of β-catenin/TCF downstream target genes cyclinD1 and c-myc. Aspirin up to 5 mM had no effect on β-catenin expression. HS-ASA also increased caspase-3 protein levels and dose-dependently increased its activity. These effects were substantially blocked by z-VAD-fmk, a pan-caspase inhibitor.
authors.affiliation: Department of Physiology, Pharmacology, and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, New York, NY 10031, USA.
authors.forename: Mitali
authors.initials: M
authors.lastname: Chattopadhyay
authors.forename: Niharika
authors.initials: N
authors.lastname: Nath
authors.forename: Ravinder
authors.initials: R
authors.lastname: Kodela
authors.forename: Tomasz
authors.initials: T
authors.lastname: Sobocki
authors.forename: Shalaka
authors.initials: S
authors.lastname: Metkar
authors.forename: Zong Yuan
authors.initials: ZY
authors.lastname: Gan
authors.forename: Khosrow
authors.initials: K
authors.lastname: Kashfi
mesh_terms: D001241:Aspirin / Q000737:chemistry* / Q000494:pharmacology*; D053148:Caspase 3 / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004789:Enzyme Activation / Q000187:drug effects; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D006862:Hydrogen Sulfide / Q000737:chemistry*; D019169:Jurkat Cells; D051176:beta Catenin / Q000235:genetics* / Q000378:metabolism
chemical_list: D051176:beta Catenin; D053148:Caspase 3; D001241:Aspirin; D006862:Hydrogen Sulfide
keywords: ALL; ASA; Apoptosis; CML; Caspase-3; Cell cycle; Chronic Myeloid Leukemia; HS-ASA; Hydrogen sulfide; Leukemia; NO; NSAIDs; Proliferation; acute lymphoblastic leukemia; aspirin; hydrogen sulfide-releasing aspirin; nitric oxide; nonsteroidal anti-inflammatory drugs; β-Catenin
references.citation: Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
references.pmid: 12184808
references.citation: Biochem Biophys Res Commun. 2005 Jan 7;326(1):93-9
references.pmid: 15567157
references.citation: Blood. 2002 Aug 1;100(3):982-90
references.pmid: 12130512
references.citation: Lancet. 2012 Apr 28;379(9826):1602-12
references.pmid: 22440946
references.citation: FASEB J. 1999 Feb;13(2):339-46
references.pmid: 9973322
references.citation: FEBS Lett. 1999 Sep 17;458(2):167-70
references.pmid: 10481058
references.citation: Curr Cancer Drug Targets. 2011 Mar;11(3):239-53
references.pmid: 21247388
references.citation: Genome Biol. 2007;8(2):R19
references.pmid: 17291332
references.citation: Dtsch Arztebl Int. 2012 Oct;109(40):652-8
references.pmid: 23094001
references.citation: Gastroenterology. 2007 Jan;132(1):261-71
references.pmid: 17241876
references.citation: Lancet. 2012 Apr 28;379(9826):1591-601
references.pmid: 22440947
references.citation: Oncogene. 2001 Feb 1;20(5):645-53
references.pmid: 11313997
references.citation: FASEB J. 2007 Dec;21(14):4070-6
references.pmid: 17634391
references.citation: J Biochem. 1996 Nov;120(5):1034-9
references.pmid: 8982873
references.citation: Blood. 1998 Aug 15;92(4):1406-14
references.pmid: 9694730
references.citation: Leukemia. 2009 Jan;23(1):109-16
references.pmid: 18818703
references.citation: Biochem Pharmacol. 2013 Mar 1;85(5):689-703
references.pmid: 23103569
references.citation: Free Radic Biol Med. 2007 Mar 1;42(5):706-19
references.pmid: 17291994
references.citation: Mol Carcinog. 2007 Apr;46(4):315-29
references.pmid: 17219422
references.citation: Biochem Pharmacol. 2012 Mar 15;83(6):715-22
references.pmid: 22222427
references.citation: Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4262-6
references.pmid: 10759547
references.citation: J Med Chem. 2011 Aug 11;54(15):5478-84
references.pmid: 21688846
references.citation: Lancet. 2008 Mar 22;371(9617):1030-43
references.pmid: 18358930
references.citation: Biochem Pharmacol. 2012 Mar 15;83(6):723-32
references.pmid: 22209867
references.citation: Int J Cell Biol. 2011;2011:738301
references.pmid: 21647292
references.citation: J Biol Chem. 2000 May 26;275(21):16345-53
references.pmid: 10748026
references.citation: Adv Pharmacol. 2009;57:31-89
references.pmid: 20230759
references.citation: Clin Cancer Res. 2011 Jan 15;17(2):286-93
references.pmid: 21097689
references.citation: Am J Pathol. 2000 Feb;156(2):545-53
references.pmid: 10666384
references.citation: Expert Rev Clin Pharmacol. 2011 Jan;4(1):109-21
references.pmid: 22115352
references.citation: Biochem Pharmacol. 2012 Mar 15;83(6):733-40
references.pmid: 22209714
references.citation: Antioxid Redox Signal. 2012 Jul 1;17(1):119-40
references.pmid: 22432697